Atlas Trials

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Clinical trial NCT06191796 · TERMINATED

Trial details

NCT number
NCT06191796
Sponsor
Exelixis
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
Start date
2024-01-25
Primary completion
2025-05-12
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.